Combat the development of white adipose tissue while simultaneously stimulating beige adipose tissue development for the reduction of unwanted fat.
Utilization of a patch aimed to show a reduction in treated fat pad size, increase whole body energy expenditure, and improve type-2 diabetesin vivoin a diet-induced obesity mouse model. Additionally, this patch aims to respond to physiological signals to deliver the necessary amount of drug to most efficiently combat fat.
As of 2016, the cost of obesity-related medical treatments was ~$210 billion/year in the US alone. With the obesity epidemic on the rise, the need for effective treatments is extremely important. Adipocytes/ fat-cells can be classified into 3 types: brown, beige and white. The brown and beige adipocytes have been shown to dissipate energy in the form of heat and offer a new way to battle obesity and its associated disorders. Studies conducted on rodents showed that activation of brown & beige adipocytes helped combat obesity & other related metabolic diseases.
The brown/beige adipocyte have also been shown to exist in humans at various ages, and the activated human brown and beige adipocytes have a therapeutic potential against obesity and diabetes. Administration of β3-adrenoceptor agonists activates brown/beige adipocytes and promotes energy expenditure. However, traditional β3-adrenoceptor agonists such as CL316, 243, L-796568, TAK-677 were not approved for use in clinical trials due to multiple side effects including increased heart rate. Thus, there is a present need for alternate technique to combat obesity in a healthy and effective manner.
Researchers at the University of New Mexico have developed the idea of an innovative skin patch that can combat the development of white adipose tissue while simultaneously stimulating beige adipose tissue development to reach the final goal of fat loss and reducing an abundance of unwanted fat in certain areas. The patch is aimed to show a reduction in treated fat pad size, increase whole body energy expenditure, and improve type-2 diabetesin vivoin a diet-induced obesity mouse model. Additionally, this patch aims to respond to physiological signals to deliver the necessary amount of drug to most efficiently combat fat.
Adipose mTORC1 Suppresses Prostaglandin Signaling and Beige Adipogenesis via the CRTC2-COX-2 Pathway
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business community (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
related metabolic diseases
traditional β3-adrenoceptor agonists
clinical trials due
multiple side effects
increased heart rate